CD38 and neoplasm: Calculation of tumor-to-background ratios (T/B-ratio) confirmed a rapidly increasing T/B-ratio of CD38-positive tumors after injection of JK36AF680 in both saline-pretreated and daratumumab-pretreated mice (Figure 5B).